Advanced MRI Scan to Tell Tumor Regrowth From Treatment Effects in Glioblastoma
Tests an advanced brain MRI to tell tumor regrowth from treatment effects in adults.
Plain-language title generated from the registry record
Registry title: Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- University Hospital BaselBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT05911230
- Record updated
- 29 January 2025
- Original description
This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.Read full original descriptionShow less
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases- AiD GLIO Pilot Trial
This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.
Inclusion: Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection; Able to give informed consent.
Exclusion: Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy); Patients in need of emergent surgery; Patients in a life-threatening condition; Age <18 Years; Histopathological analyses of insufficient quality; Unable to give informed consent.